Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St climbs as Mideast tensions ease, Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast to split cable business from media in NBCUniversal, Sky spinoff
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat
May 6, 2021 7:51 AM EDTSyros Pharmaceuticals (NASDAQ: SYRS) reported Q1 EPS of ($0.23), $0.23 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.83 million versus the consensus estimate of $2.67 million.
First Quarter 2021 Financial Results
Revenues were $4.8 million for the first quarter of 2021, consisting of $4.0 million in revenue recognized under Syros collaboration with Global Blood Therapeutics, Inc. (GBT) and $0.8 million recognized under its collaboration with Incyte Corporation (Incyte). Syros recognized $2.4 million in revenue in the first quarter of 2020, including $2.2 million under its collaboration with GBT and $0.2 million under its collaboration with Incyte.Research and... More